重磅研究搶先看，TNBC、HR+乳腺癌前沿5分鐘速覽！| 2024 SABCS

*僅供醫學專業人士閱讀參考

直擊2024 SABCS，見證乳腺癌治療革新

整理 | lily

2024年12月10日-13日，第47屆聖安東尼奧乳腺癌研討會（SABCS）將在美國聖安東尼奧隆重舉行。作爲乳腺癌研究領域中規模最大、最具盛名的科學聚會之一，SABCS大會集結了近一年來乳腺癌領域的最新研究成果、臨牀實踐經驗、治療進展和技術創新等內容。

日前，大會公佈了摘要標題。醫學界特整理部分LBA Oral Session、General Session、Rapid Fire Session的口頭報告研究，分類爲HR+/HER2-乳腺癌、三陰性乳腺癌（TNBC），以供讀者參考。

HR+/HER2-乳腺癌

摘要號：LB1-03

Primary results of the randomised Phase III trial comparing first-line ET plus palbociclib vs standard mono-chemotherapy in women with high risk HER2-/HR+ metastatic breast cancer and indication for chemotherapy - PADMA study.

一線內分泌治療（ET）聯合哌柏西利vs標準單藥化療用於具備化療指徵的高危HR+/HER2-轉移性女性乳腺癌患者中療效的隨機III期試驗——PADMA研究主要結果。

講者：Sibylle Loibl, German Cooperative Group, Neu-Isenburg, Germany

摘要號：LB1-04

Efficacy and safety of trastuzumab deruxtecan (T-DXd) vs physician’s choice of chemotherapy (TPC) by pace of disease progression on prior endocrine-based therapy: additional analysis from DESTINY-Breast06.

根據既往以ET爲基礎的方案治療的疾病進展速度，德曲妥珠單抗（T-DXd）vs醫生選擇的化療（TPC）療效和安全性：DESTINY-Breast06的事後分析。

講者：Aditya Bardia, UCLA David Geffen School of Medicine, Los Angeles, California

摘要號：LB1-05

ROSC (Neo) adjuvant nab-PAC weekly vs sb-PAC q2w, followed by EC q2w, in genomically or clinically high-risk HR+/HER- early breast cancer according to ET-response: final survival results from the WSG ADAPT-HR+/HER2- chemotherapy-trial.

根據內分泌治療療效，ROSC（新）輔助白蛋白紫杉醇每週1次vs 溶劑型紫杉醇每兩週1次，序貫EC化療每兩週1次，用於遺傳性或臨牀高危HR+/HER-早期乳腺癌：WSG ADAPT-HR+/HER2-化療試驗的最終生存結果。

講者：Sherko Kuemmel, German Medical Institute, Limassol, Germany

摘要號：LB1-06

Primary results of SOLTI VALENTINE: neoadjuvant randomized phase II trial of HER3-DXd alone or in combination with letrozole for high-risk hormone receptor positive (HR+)/HER2-negative (neg) early breast cancer (EBC).

SOLTI VALENTINE研究的主要結果：一項旨在評估HER3-DXd± 來曲唑治療高危HR+/HER2-早期乳腺癌（EBC）的新輔助隨機II期試驗。

講者：Mafalda Oliveira, Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain

摘要號：GS1-01

Imlunestrant, an Oral Selective Estrogen Receptor Degrader (SERD), as Monotherapy and Combined with Abemaciclib, for Patients w/ ER+, HER2- Advanced Breast Cancer (ABC), Pretreated w/ Endocrine Therapy (ET): Results of the Phase 3 EMBER-3 trial.

Imlunestrant，一種口服選擇性雌激素受體降解劑（SERD），聯合或不聯合阿貝西利用於接受過ET的ER+/HER2-晚期乳腺癌（ABC）患者：III期EMBER-3試驗結果。

講者：Komal Jhaveri, Memorial Sloan Kettering Cancer Center, New York, New York

摘要號：GS2-01

Exclusive endocrine therapy or radiation therapy in women aged 70+ years with luminal-like early breast cancer (EUROPA): preplanned interim analysis of a randomized phase 3 trial.

個性化ET或放射治療用於70歲以上luminal型早期乳腺癌女性患者（EUROPA）：一項隨機III期試驗的預設中期分析。

講者：Icro Meattini, University of Florence, Florence, Italy

摘要號：GS3-03

Impact of Anthracyclines in High Genomic Risk Node-Negative HR+/HER2- Breast Cancer.

蒽環類藥物在高基因組風險淋巴結陰性HR+/HER2-乳腺癌中的影響。

講者：Nan Chen, University of Chicago Medicine, Chicago, Illinois

摘要號：GS3-09

Multimodal integration of real world clinical and genomic data for the prediction of CDK4/6 inhibitors outcomes in patients with HR+/HER2- metastatic breast cancer.

多模態整合真實世界臨牀和基因組數據，以預測HR+/HER2-轉移性乳腺癌患者中CDK4/6抑制劑的療效。

講者：Enrico Moiso, Memorial Sloan Kettering Cancer Center, New York, New York

摘要號：RF3-01

TBCRC 056: A phase II study of neoadjuvant niraparib with dostarlimab for patients with BRCA- or PALB2-mutated breast cancer: Results from the ER+/HER2- cohort.

II期TBCRC 056研究的ER+/HER2-隊列的結果：一項新輔助尼拉帕利聯合dostarlimab治療BRCA或PALB2突變乳腺癌患者。

講者：Erica Mayer, Dana-Farber Cancer Institute, Boston, Massachusetts

TNBC

摘要號：LB1-07

Exploratory Biomarker Analysis of the Phase 3 KEYNOTE-522 Study of Neoadjuvant Pembrolizumab or Placebo Plus Chemotherapy Followed by Adjuvant Pembrolizumab or Placebo for Early-Stage TNBC.

早期TNBC患者接受新輔助帕博利珠單抗±化療後，帕博利珠單抗或安慰劑輔助治療的III期KEYNOTE-522研究探索性生物標誌物分析。

講者：Joyce O’Shaughnessy, Baylor-Sammons Cancer Center, Dallas, Texas

摘要號：GS3-05

NSABP B-59/GBG-96-GeparDouze: A randomized double-blind phase III clinical trial of neoadjuvant chemotherapy with atezolizumab or placebo followed by adjuvant atezolizumab or placebo in patients with Stage II and III triple-negative breast cancer.

NSABP B-59/GBG-96-GeparDouze研究：一項評估化療聯合阿替利珠單抗/安慰劑新輔助治療，隨後阿替利珠單抗/安慰劑輔助治療II/III期三TNBC療效的隨機、雙盲、3期臨牀試驗。

講者：Charles Geyer, University of Pittsburgh, Pittsburgh, Pennsylvania

摘要號：GS3-06

Neoadjuvant camrelizumab plus chemotherapy (chemo) for early or locally advanced triple-negative breast cancer (TNBC): a randomized, double-blind, phase 3 trial.

卡瑞利珠單抗聯合化療（chemo）新輔助治療早期或局部晚期TNBC：一項隨機、雙盲、III期試驗。

講者：邵志敏教授，復旦大學附屬腫瘤醫院

摘要號：RF3-02

Efficacy of adjuvant avelumab by PD-L1, tumor infiltrating lymphocytes and residual cancer burden in high-risk triple negative breast cancer: secondary and exploratory endpoints of the phase III A-BRAVE trial.

根據PD-L1、腫瘤浸潤性淋巴細胞和殘留癌症負擔評估輔助avelumab治療高風險TNBC的療效：III期A-BRAVE試驗的次要和探索性終點。

講者：Maria Vittoria Dieci, University of Padua, Padua, Italy

摘要號：RF3-03

Nivolumab + Ipilimumab (NIVO+IPI) compared to capecitabine for triple-negative breast cancer patients with residual disease after neoadjuvant chemotherapy – Final results of BreastImmune-03, a multicenter randomized open-label phase II trial.

納武利尤單抗+伊匹木單抗（NIVO+IPI）vs卡培他濱用於新輔助化療後有殘留病竈的TNBC患者的療效——多中心、隨機、開放標籤、II期BreastImmune-03研究的最終結果。

講者：Olivier Trédan, Centre Lèon Bèrard, Lyon, France

精彩資訊等你來

責任編輯：Sheep

*醫學界力求其發表內容專業、可靠，但不對內容的準確性做出承諾；請相關各方在採用或以此作爲決策依據時另行覈查。